Balla Nathalie 4

Accession 0001576427-23-000039

CIK 0001576427other

View on SEC.gov Company Profile

Filed

Mar 7, 7:00 PM ET

Accepted

Mar 8, 4:17 PM ET

Size

26.5 KB

Accession

0001576427-23-000039

Insider Transaction Report

Form 4

Period: 2023-03-06

Criteo S.A.CRTO

Balla Nathalie

Director

Transactions

Sale
Ordinary Shares
2023-03-07$32.02/sh−4,846$155,193→ 17,800 total
Sale
Ordinary Shares
2023-03-06$32.35/sh−12,177$393,987→ 17,800 total
Exercise/Conversion
Non-employee Warrant (right to buy)
2023-03-06−2,600→ 22,400 total
Exercise: $20.90Exp: 2028-10-25→ Ordinary Shares (2,600 underlying)
Exercise/Conversion
Non-employee Warrant (right to buy)
2023-03-06−12,177→ 14,243 total
Exercise: $18.49Exp: 2029-10-24→ Ordinary Shares (12,177 underlying)
Exercise/Conversion
Ordinary Shares
2023-03-06$20.90/sh+2,600$54,340→ 20,400 total
Sale
Ordinary Shares
2023-03-06$32.67/sh−2,600$84,952→ 17,800 total
Exercise/Conversion
Ordinary Shares
2023-03-06$18.49/sh+12,177$225,153→ 29,977 total
Exercise/Conversion
Ordinary Shares
2023-03-06$20.90/sh+22,400$468,160→ 40,200 total
Sale
Ordinary Shares
2023-03-06$32.35/sh−22,400$724,752→ 17,800 total
Exercise/Conversion
Ordinary Shares
2023-03-07$18.62/sh+4,846$90,233→ 22,646 total
Exercise/Conversion
Non-employee Warrant (right to buy)
2023-03-06−22,400→ 0 total
Exercise: $20.90Exp: 2028-10-25→ Ordinary Shares (22,400 underlying)
Exercise/Conversion
Non-employee Warrant (right to buy)
2023-03-07−4,846→ 9,397 total
Exercise: $18.62Exp: 2029-10-24→ Ordinary Shares (4,846 underlying)

Footnotes (10)

[F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
[F10]Warrant granted on October 24, 2019. One-fourth of the grant vested on the first anniversary of the grant date and an additional 1/16th of the grant vested quarterly thereafter. Warrant is set to expire on October 24, 2029.
[F2]The exercise price of the non-employee warrant is 19.71 euros. The U.S. dollar equivalent of the exercise price is $20.90 using the exchange rate as of March 6, 2023 (1.00 = $0.9431).
[F3]For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission.
[F4]The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $32.51 to $32.77 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F5]The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $32.00 to $ 32.845 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F6]The exercise price of the non-employee warrant is 17.44 euros. The U.S. dollar equivalent of the exercise price is $18.49 using the exchange rate as of March 6, 2023 (1.00 = $ 0.9431).
[F7]The exercise price of the non-employee warrant is 17.44 euros. The U.S. dollar equivalent of the exercise price is $18.62 using the exchange rate as of March 7, 2023 (1.00 = $ 0.9366).
[F8]The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.19 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F9]Warrant granted on October 25, 2018. One-fourth of the grant vested on the first anniversary of the grant date and an additional 1/16th of the grant vested quarterly thereafter. Warrant is set to expire on October 25, 2028.

Documents

1 file

4
wf-form4_167831021346880.xmlPrimary
FORM 4

Issuer

Criteo S.A.

CIK 0001576427

→

Entity typeother

Related Parties

filerCIK 0001711277

Filing Metadata

Form type: 4
Filed: Mar 7, 7:00 PM ET
Accepted: Mar 8, 4:17 PM ET
Size: 26.5 KB

View on SEC.gov